Defining the Ablative Dose for Y-90 TARE
Defining the Ablative Dose for Y-90 TARE
Recruiting · NCT07586046 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Defining the Ablative Dose for Y-90 TARE | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Margins of Excision, Morphological and Microscopic Findings, Neoplasms by Histologic Type, Neoplasms by Site, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2026-09-15 | NCT07586046 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Northwestern University | 381 |
| Radiological Society of North America | 7 |
| Robert H. Lurie Cancer Center | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Northwestern University | Chicago | United States | 727 |